Jenny Goins, interim head of the National Alliance of Healthcare Purchaser Coalitions, says employers need the same visibility into medical benefits that a new Department of Labor rule gives them into PBM compensation.
News|Articles|January 1, 2003
Duloxetine: An antidepressant that inhibits both norepinephrine and serotonin uptake
Duloxetine is a reuptake inhibitor at serotonergic and noradrenergic neurons and appears to have low affinity for other neurotransmitter systems. In three published clinical trials in patients with MDD, duloxetine was well tolerated and more effective than placebo. Further study is needed to compare its efficacy with that of other antidepressants, to prospectively assess time to onset of antidepressant effect, and to clarify effects on somatic symptoms and potential adverse cardiovascular and sexual effects. Duloxetine is also under investigation for the treatment of stress urinary incontinence in women (trade name to be determined, comarketed by Lilly and Boehringer Ingelheim). Preliminary information suggests that duloxetine therapy reduces the number of incontinence episodes. Duloxetine has been deemed ?approvable? for the treatment of MDD and will be comarketed under the trade name Cymbalta by Eli Lilly and Company and Quintiles.
Advertisement
Advertisement
Related to this article
Only 19% of community oncologists use AI predictive models. Prerna Mewawalla, M.D., outlines six ways AI can already help in myeloma care.
Jamilia Sherls, DNP, says health systems should track vaccine coverage closely and look to AAP schedules if federal guidance isn't evidence-based.
People with ADHD had a 70% higher risk of death from any cause in a 19-study meta-analysis, with excess deaths from suicide, injury and natural causes.
Bronchiectasis affected 221.6 per 100,000 people in the U.S. over five years, which is higher than earlier national estimates, according to a study published in CHEST.
Cepheid’s Xpert Respiratory Panel, which tests one swab for nine viruses and four bacteria, is now certified for sale in Europe under the IVDR.
A study of 1,068 adults found whole-blood NAD fell in those with cardiovascular disease and hypertension but did not decline with age.
Adding Sunharbo (asundexian), a first-in-class factor XI inhibitor, to single or dual antiplatelet therapy reduces ischemic stroke risk without increasing the risk of major bleeding.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Vaccine schedule overhaul could put coverage at risk, state official says
2
Six jobs for AI in myeloma care, from Prerna Mewawalla, M.D.
3
Patience and persistence define one Yale gastroenterologist’s approach to MASLD
4
Bronchiectasis is more common in the U.S. than a decade ago, study finds
5